MedKoo Cat#: 562282 | Name: Cariporide Mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cariporide Mesylate is a selective Na+/H+ exchanger isoform 1 (NHE1) inhibitor.

Chemical Structure

Cariporide Mesylate
Cariporide Mesylate
CAS#159138-81-5 (mesylate)

Theoretical Analysis

MedKoo Cat#: 562282

Name: Cariporide Mesylate

CAS#: 159138-81-5 (mesylate)

Chemical Formula: C13H21N3O6S2

Exact Mass: 379.0872

Molecular Weight: 379.44

Elemental Analysis: C, 41.15; H, 5.58; N, 11.07; O, 25.30; S, 16.90

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Cariporide Mesylate; Cariporide Mesylate salt; HOE642; HOE-642; HOE 642; Cariporide mesilate
IUPAC/Chemical Name
N-(Aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide Mesylate
InChi Key
FNDLQABGYJQJPH-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H17N3O3S.CH4O3S/c1-7(2)9-5-4-8(11(16)15-12(13)14)6-10(9)19(3,17)18;1-5(2,3)4/h4-7H,1-3H3,(H4,13,14,15,16);1H3,(H,2,3,4)
SMILES Code
O=C(NC(N)=N)C1=CC=C(C(C)C)C(S(=O)(C)=O)=C1.OS(=O)(C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 379.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mihaila RG. A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Dec;159(4):519-26. doi: 10.5507/bp.2015.060. Epub 2015 Nov 27. Review. PubMed PMID: 26725705. 2: Ma D, Fang Q, Wang P, Gao R, Wu W, Lu T, Cao L, Hu X, Wang J. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells. J Biol Chem. 2015 May 15;290(20):12558-71. doi: 10.1074/jbc.M114.626960. Epub 2015 Mar 23. PubMed PMID: 25802333; PubMed Central PMCID: PMC4432277. 3: Hu RH, Jin WN, Chang GQ, Lin YN, Wang J, Ru YX, Li QH, Pang TX. [Increasing sensitivity of leukemia cells to imatinib by inhibiting NHE1 and p38MAPK signaling pathway]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Dec;20(6):1341-5. Chinese. PubMed PMID: 23257429. 4: Jin W, Li Q, Lin Y, Lu Y, Li H, Wang L, Hu R, Ma L, Wang J, Pang T. Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger. Cancer Lett. 2011 Sep 1;308(1):81-90. doi: 10.1016/j.canlet.2011.04.016. Epub 2011 May 14. PubMed PMID: 21576001. 5: Stanbouly S, Kirshenbaum LA, Jones DL, Karmazyn M. Sodium hydrogen exchange 1 (NHE-1) regulates connexin 43 expression in cardiomyocytes via reverse mode sodium calcium exchange and c-Jun NH2-terminal kinase-dependent pathways. J Pharmacol Exp Ther. 2008 Oct;327(1):105-13. doi: 10.1124/jpet.108.140228. Epub 2008 Jul 23. PubMed PMID: 18650245. 6: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408. PubMed PMID: 12851663. 7: Maczewski M, Beresewicz A. Role of nitric oxide and free radicals in cardioprotection by blocking Na+/H+ and Na+/Ca2+ exchange in rat heart. Eur J Pharmacol. 2003 Feb 14;461(2-3):139-47. PubMed PMID: 12586209. 8: Touret N, Poujeol P, Counillon L. Second-site revertants of a low-sodium-affinity mutant of the Na+/H+ exchanger reveal the participation of TM4 into a highly constrained sodium-binding site. Biochemistry. 2001 Apr 24;40(16):5095-101. PubMed PMID: 11305927. 9: Gumina RJ, Buerger E, Eickmeier C, Moore J, Daemmgen J, Gross GJ. Inhibition of the Na(+)/H(+) exchanger confers greater cardioprotection against 90 minutes of myocardial ischemia than ischemic preconditioning in dogs. Circulation. 1999 Dec 21-28;100(25):2519-26; discussion 2469-72. PubMed PMID: 10604890.